Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
Caterina Peraldo‐Neia(Candiolo Cancer Institute), Francesco Leone(Istituto Oncologico Veneto)
Cited by 8
Related Papers
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study
|The Lancet Oncology|2019|188